Literature DB >> 6715089

Nifedipine plasma concentration in patients treated for angina pectoris.

Z Stern, E Zylber-Katz, M Levy.   

Abstract

Nifedipine, a "calcium channel blocker", is increasingly employed in the treatment of angina pectoris. Large interindividual differences have been observed in the effective dosage of the drug. Many of the reported alleged adverse reactions to nifedipine are linked to its primary pharmacologic action - vasodilatation. Therefore in 15 patients with angina pectoris we studied the relation between nifedipine concentration in the plasma and its clinical effects. Although in individual patients an increase in daily dose from 30 to 50 mg was followed by increased plasma levels and cessation of anginal attacks, no "therapeutic plasma range" could be delineated. Similarly, although some patients developed a headache when relatively high levels were measured, these levels still overlapped with those found in asymptomatic patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6715089

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  9 in total

Review 1.  The combination of slow-release nifedipine and atenolol for stable angina.

Authors:  D G Waller; V F Challenor
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 3.  Beta-adrenoceptor antagonists plus nifedipine in the treatment of chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; C F George
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

4.  The trans-hepatic extraction of nifedipine.

Authors:  V F Challenor; D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

5.  Slow release nifedipine plus atenolol in chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

6.  Clinical and rheological effects of nifedipine in Raynaud's phenomenon.

Authors:  D G Waller; V F Challenor; D A Francis; O S Roath
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

Review 7.  Nifedipine. Relationship between pharmacokinetics and pharmacodynamics.

Authors:  C H Kleinbloesem; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

8.  Human lymphatic vessel contractile activity is inhibited in vitro but not in vivo by the calcium channel blocker nifedipine.

Authors:  Niklas Telinius; Sheyanth Mohanakumar; Jens Majgaard; Sukhan Kim; Hans Pilegaard; Einar Pahle; Jørn Nielsen; Marc de Leval; Christian Aalkjaer; Vibeke Hjortdal; Donna Briggs Boedtkjer
Journal:  J Physiol       Date:  2014-08-28       Impact factor: 5.182

9.  Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers.

Authors:  T J Walley; A M Heagerty; K L Woods; R F Bing; J E Pohl; D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.